Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 – 2014)

Bibliography

• Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39
   PubMed Web of Science ®Google Scholar
• Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Milestones in cell division : To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31
   PubMed Web of Science ®Google Scholar
• Lim SH, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 2013;140:3079-93
   PubMed Web of Science ®Google Scholar
• Porter DC, Zhang N, Danes C, et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001;21:6254-69
   PubMed Web of Science ®Google Scholar
• Bruyere C, Meijer L. Targeting cyclin-dependent kinases in anti-neoplastic therapy. Curr Opin Cell Biol 2013;25:772-9
   PubMed Web of Science ®Google Scholar
• Fischer PM, Endicott J, Meijer L. Cyclin-dependent kinase inhibitors. Prog Cell Cycle Res 2003;5:235-48
   PubMedGoogle Scholar
• Chao SH, Fujinaga K, Marion JE, et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000;275:28345-8
   PubMed Web of Science ®Google Scholar
• Whittaker SR, Walton MI, Garrett MD, Workman P. The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res 2004;64:262-72
   PubMed Web of Science ®Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015;14:130-46
   PubMed Web of Science ®Google Scholar
• Mariaule G, Belmont P. Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? a short survey. Molecules 2014;19:14366-82
   PubMed Web of Science ®Google Scholar
• Goh KC, Novotny-Diermayr V, Hart S, et al. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia 2012;26:236-43
   PubMed Web of Science ®Google Scholar
• Albanese C, Alzani R, Amboldi N, et al. Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy. Mol Cancer Ther 2010;9:2243-54
   PubMed Web of Science ®Google Scholar
• Guzi TJ, Paruch K, Dwyer MP, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther 2011;10:591-602
   PubMed Web of Science ®Google Scholar
• Daud AI, Ashworth MT, Strosberg J, et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol 2015;33(9):1060-6
   PubMed Web of Science ®Google Scholar
• Smolewski P. Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs 2008;11:204-14
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427-37
   PubMed Web of Science ®Google Scholar
• First CDK 4/6 inhibitor heads to market. Cancer Discov 2015;5(4):339-40
   Google Scholar
• Thangavel C, Dean JL, Ertel A, et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer 2011;18:333-45
   PubMed Web of Science ®Google Scholar
• Puyol M, Martin A, Dubus P, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010;18:63-73
   PubMed Web of Science ®Google Scholar
• Molenaar JJ, Ebus ME, Geerts D, et al. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci USA 2009;106:12968-73
   PubMed Web of Science ®Google Scholar
• Kang J, Sergio CM, Sutherland RL, Musgrove EA. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer 2014;14:32
   PubMed Web of Science ®Google Scholar
• Novartis, Astex Therapeutics. Pyrrolopyrimidine compounds as cdk inhibitors. WO020675A1; 2010
   Google Scholar
• Novartis. Pyrrolopyrimidine compounds as inhibitors of cdk4/6. WO101409A1; 2011
   Google Scholar
• Amgen. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors. WO085185A1; 2009
   Google Scholar
• Tavares FX, Strum JC. Cdk inhibitors. WO061156A1; 2012
   Google Scholar
• G1 Therapeutics. Transient protection of normal cells during chemotherapy. WO144326A1; 2014
   Google Scholar
• Novartis. Pharmaceutical combination comprising binimetinib. WO097125A1; 2014
   Google Scholar
• Novartis. Combination therapy. WO085318A1; 2014
   Google Scholar
• Novartis. Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer. WO130232A1; 2011
   Google Scholar
• Weiss GJ, Hidalgo M, Borad MJ, et al. Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. Invest New Drugs 2012;30:2334-43
   PubMed Web of Science ®Google Scholar
• Nerviano Medical Sciences. Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide. WO058006A1; 2010
   Google Scholar
• Nerviano Medical Sciences. Use of a cdk inhibitor for the treatment of glioma. WO012733A1; 2010
   Google Scholar
• Nerviano Medical Sciences. Therapeutic combination comprising a cdks inhibitor and an antineoplastic agent. WO012777A1; 2010
   Google Scholar
• Nerviano Medical Sciences. Cdk inhibitor salts. WO125004A1; 2010
   Google Scholar
• Novartis, Astex. Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof. US0115878A1; 2012
   Google Scholar
• Pfizer. Solid forms of a selective cdk4/6 inhibitor. WO128588A1; 2014
   Google Scholar
• Novartis. Deuterated pyrrolopyrimidine compounds as inhibitors of cdk4/6. WO101417A1; 2011
   Google Scholar
• Piramal. A process for preparation of an intermediate of the pyrrolidine substituted flavones. WO128523A1; 2014
   Google Scholar
• Piramal. An improved process for preparation of an intermediate of the pyrrolidine substituted flavones. WO128524A1; 2014
   Google Scholar
• Council of Scientific and Industrial Research. Rohitukine analogs as cyclin-dependent kinase inhibitors and a process for the preparation thereof. WO170914A1; 2014
   Google Scholar
• The Hong Kong University of Science and Technology. Cdk5 inhibitors and therapeutic uses thereof. WO069334A1; 2011
   Google Scholar
• Tragara Pharmaceuticals, S*Bio. Solid state forms of macrocyclic kinase inhibitors. WO097525A1; 2011
   Google Scholar
• CNIO. Macrocyclic compounds and their use as cdk8 inhibitors. WO001310A1; 2013
   Google Scholar
• Jorda R, Paruch K, Krystof V. Cyclin-dependent kinase Inhibitors Inspired by Roscovitine: Purine Bioisosteres. Curr Pharm Des 2012;18:2974-80
   PubMed Web of Science ®Google Scholar
• Palacký University Olomouc. Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containing these derivatives. WO139289A1; 2010
   Google Scholar
• Palacký University Olomouc. Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds. WO085924A2; 2010
   Google Scholar
• Palacký University Olomouc. 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions. WO121764A2; 2014
   Google Scholar
• Gucky T, Jorda R, Zatloukal M, et al. A novel series of highly potent 2,6,9-Trisubstituted purine cyclin-dependent kinase inhibitors. J Med Chem 2013;56:6234-47
   PubMed Web of Science ®Google Scholar
• Haider C, Grubinger M, Reznickova E, et al. Novel inhibitors of cyclin-dependent kinases combat hepatocellular carcinoma without inducing chemoresistance. Mol Cancer Ther 2013;12:1947-57
   PubMed Web of Science ®Google Scholar
• Georgetown University. Fluorescent cdk inhibitors for treatment of cancer. WO019967A1; 2010
   Google Scholar
• Parry D, Guzi T, Shanahan F, et al. Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor. Mol Cancer Ther 2010;9:2344-53
   PubMed Web of Science ®Google Scholar
• Schering Corp. 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors. WO070567A1; 2009
   Google Scholar
• Centre National de la Recherche Scientifique. Perharidines as cdk inhibitors. WO034411A1; 2009
   Google Scholar
• Centre National de la Recherche Scient. Perharidines as cdk inhibitors. WO034475A2; 2009
   Google Scholar
• Centre National De La Recherche Scientifique. Perharidines as cdk inhibitors. US0280065A1; 2010
   Google Scholar
• Centre National de la Recherche Scientifique. Preparation of pyrazolo[1,5-a]-1,3,5-triazine derivatives as inhibitors of cyclin-dependent kinases, casein kinase 1 and DYRK1A kinase for treating diseases including B-cell chronic lymphoid leukemia. FR2943058A1; 2010
   Google Scholar
• Centre National De La Recherche Scientifique. Pyrazolo[1,5-a]-1,3,5-triazine derivatives, preparation thereof, and therapeutic use thereof. WO103486A1; 2010
   Google Scholar
• Lead Discovery Center. Pharmaceutically active pyrazolo-triazine derivatives. WO128029A1; 2013
   Google Scholar
• Lead Discovery Center. Pyrazolo-triazine derivatives as selective cyclin- dependent kinase inhibitors. WO128028A1; 2013
   Google Scholar
• Hoessel R, Leclerc S, Endicott JA, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999;1:60-7
   PubMed Web of Science ®Google Scholar
• Scott EN, Thomas AL, Molife LR, et al. A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI((TM))), in patients with advanced solid tumours. Cancer Chemother Pharmacol 2009;64:425-9
   PubMed Web of Science ®Google Scholar
• Anygen. Indirubin-3’-oxime derivatives as potent cyclin dependent kinase inhibitors. WO096676A2; 2011
   Google Scholar
• Gilead. Oxindolyl inhibitor compounds. WO009166A1; 2010
   Google Scholar
• Senex Biotechnology. Specific inhibitors of cdk3. WO089450A1; 2014
   Google Scholar
• Noscira. Indole-pyrimidine derivatives and their therapeutic uses. WO149976A1; 2013
   Google Scholar
• De Montfort University. Compounds and uses. CA2597193A1; 2009
   Google Scholar
• Selvita. Substituted tricyclic benzimidazoles as kinase inhibitors. WO072435A1; 2014
   Google Scholar
• Novartis, Astex Therapeutics. Imidazole derivatives and their use as modulators of cyclin dependent kinases. WO125402A1; 2010
   Google Scholar
• Bayer. Disubstituted 5-fluoro-pyrimidines. WO037896A1; 2013
   Google Scholar
• Bayer. Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group. WO037894A1; 2013
   Google Scholar
• Bayer. N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group. WO060493A2; 2014
   Google Scholar
• Bayer. 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group. WO160034A1; 2012
   Google Scholar
• Lead Discovery Center, Bayer. Pharmaceutically active disubstituted pyridine derivatives. WO117059A1; 2012
   Google Scholar
• Bayer. 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group. WO060375A2; 2014
   Google Scholar
• Bayer. 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group. WO076091A1; 2014
   Google Scholar
• Bayer. 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group. WO060376A1; 2014
   Google Scholar
• Bayer. 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group. WO076028A1; 2014
   Google Scholar
• Bayer. N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group. WO076111A1; 2014
   Google Scholar
• Lead Discovery Center GMBH, Max-Planck-Gesellschaft. Cdk9 inhibitors in the treatment of midline carcinoma. WO026874A1; 2013
   Google Scholar
• Gilead. Fused heterocyclyc inhibitor compounds. WO009155A2; 2010
   Google Scholar
• Dana-Farber Cancer Institute. Inhibitors of cyclin-dependent kinase 7 (cdk7). WO063068A1; 2014
   Google Scholar
• Kwiatkowski N, Zhang TH, Rahl PB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 2014;511:616-20
   PubMed Web of Science ®Google Scholar
• The University of Nottingham. Pyrimidines, triazines and their use as pharmaceutical agents. WO118567A2; 2009
   Google Scholar
• Cyclacel. N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds. WO029248A1; 2003
   Google Scholar
• Cyclacel. Inhibitors of cyclin dependent kinases as anti-cancer agent. WO079193A1; 2002
   Google Scholar
• Cancer Research Technology. Therapeutic compounds. WO156780A1; 2013
   Google Scholar
• Lam F, Abbas AY, Shao H, et al. Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. Oncotarget 2014;5:7691-704
   PubMed Web of Science ®Google Scholar
• Walsby E, Pratt G, Shao H, et al. A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. Oncotarget 2014;5:375-85
   PubMed Web of Science ®Google Scholar
• Gilead. Imidazolyl pyrimidine inhibitor compounds. US0009990A1; 2010
   Google Scholar
• Novartis. Pyrazinylpyridines useful for the treatment of proliferative diseases. WO026904A1; 2011
   Google Scholar
• Novartis. Bipyridines useful for the treatment of proliferative diseases. WO026911A1; 2011
   Google Scholar
• Novartis. Heteroaryl compounds as kinase inhibitors. WO026917A1; 2011
   Google Scholar
• Novartis. Phenyl-heteroaryl amine compounds and their uses. WO066065A1; 2012
   Google Scholar
• Novartis. 3-(aminoaryl)-pyridine compounds. WO066070A1; 2012
   Google Scholar
• Ingenium Pharmaceuticals. Inhibitors of protein kinases. WO047359A1; 2009
   Google Scholar
• Nerviano Medical Sciences. Crystalline cdc7 inhibitor salts. WO057960A1; 2011
   Google Scholar
• Nerviano Medical Sciences. Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamides. WO054714A1; 2011
   Google Scholar
• Senex Biotechnology. Cdki pathway inhibitors and uses thereof. US0071477A1; 2012
   Google Scholar
• Porter DC, Roninson IB, Wentland MP. Cdki pathway inhibitors and uses thereof. US0378683A1; 2014
   Google Scholar
• Senex Biotechnology. Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer. WO116786A1; 2013
   Google Scholar
• Senex Biotechnology. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer. WO134169A1; 2014
   Google Scholar
• University of South Carolina. Method for treating prostate cancer. WO071143A1; 2014
   Google Scholar
• Wyeth. Anticancer agents; cyclin dependent kinase inhibitors; (4Z)-6-[(3-aminophenyl)amino]-4-(([4-(piperidin-1-ylmethyl)phenyl]amino)methylene)isoquinoline-1,3(2H,4H)-dione for example. US7713994B2; 2010
   Google Scholar
• Icahn School of Medicine at Mount Sinai. Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof. US0086941A1; 2014
   Google Scholar
• Sanofi. Preparation of naphthyridine and isoquinoline derivatives as CDK inhibitors. INKO01289A; 2011
   Google Scholar
• Curis. Cdk inhibitors containing a zinc binding moiety. WO036016A1; 2009
   Google Scholar
• Curis. Cdk inhibitors. WO075542A1; 2010
   Google Scholar
• Schering Corp. Diamido thiazole derivatives as protein kinase inhibitors. WO058730A1; 2009
   Google Scholar
• Schering Corp. Heterocyclic urea and thiourea derivatives and methods of use thereof. WO058739A1; 2009
   Google Scholar
• Schering Corp. Thiazole carboxamide derivatives and their to treat cancer. WO058729A2; 2009
   Google Scholar
• Chhabria MT, Patel SM, Suthar MP, et al. Preparation of 4-amino-3,5-disubstituted-thiazole-2(3H)-thione/one series as novel class of CDK2 inhibitors. INMU01493A; 2009
   Google Scholar
• Crystal Biopharmaceuticals. Nitrogen mustard derivatives. WO049279A2; 2013
   Google Scholar
• Peyressatre M, Prevel C, Pellerano M, Morris MC. Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers 2015;7:179-237
   PubMed Web of Science ®Google Scholar
• Giordano A. Peptide inhibitors of cyclin-dependent kinase activity and uses thereof. US0054333A1; 2009
   Google Scholar
• Cai DP, Latham VM, Zhang XX, Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006;66:9270-80
   PubMed Web of Science ®Google Scholar
• Du JY, Widlund HR, Horstmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 2004;6:565-76
   PubMed Web of Science ®Google Scholar
• Santamaria D, Barriere C, Cerqueira A, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007;448:811-U8
   PubMed Web of Science ®Google Scholar
• Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689-98
   PubMed Web of Science ®Google Scholar
• Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-U122
   PubMed Web of Science ®Google Scholar
• Bommi-Reddy A, Almeciga I, Sawyer J, et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci USA 2008;105:16484-9
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhu YH, Mao CQ, et al. Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles. J Control Release 2014;192:114-21
   PubMed Web of Science ®Google Scholar
• Huang CH, Lujambio A, Zuber J, et al. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev 2014;28:1800-14
   PubMed Web of Science ®Google Scholar
• Turner NC, Lord CJ, Iorns E, et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. Embo J 2008;27:1368-77
   PubMed Web of Science ®Google Scholar
• Bajrami I, Frankum JR, Konde A, et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res 2014;74:287-97
   PubMed Web of Science ®Google Scholar